Skip to Main Content

Author Details

Jaya Sangodkar
University of Michigan ann arbor
2008
29
21
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37644036Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.Nat Commun2023
37644036Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.Nat Commun2023
34921012Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.Cancer Res2022
34921012Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.Cancer Res2022
33568357PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.Mol Cancer Ther2021
33568357PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.Mol Cancer Ther2021
31541192Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.Oncogene2020
31822503Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.J Biol Chem2020
32531271Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.Cancer Cell2020
33027304The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.PLoS One2020
31541192Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.Oncogene2020
31822503Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers.J Biol Chem2020
33027304The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies.PLoS One2020
32531271Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.Cancer Cell2020
30401535Targeting PP2A in cancer: Combination therapies.Biochim Biophys Acta Mol Cell Res2019
30401535Targeting PP2A in cancer: Combination therapies.Biochim Biophys Acta Mol Cell Res2019
31142515The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.Cancer Res2019
30830869Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.JCI Insight2019
30830869Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.JCI Insight2019
31142515The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis.Cancer Res2019
29107183Therapeutic targeting of PP2A.Int J Biochem Cell Biol2018
30021885PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.Sci Transl Med2018
30206106Sprague Dawley <i>Rag2</i>-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts.Mol Cancer Ther2018
29358171Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.Cancer Res2018
29107183Therapeutic targeting of PP2A.Int J Biochem Cell Biol2018
29725697The impact of phosphatases on proliferative and survival signaling in cancer.Cell Mol Life Sci2018
30021885PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.Sci Transl Med2018
30206106Sprague Dawley <i>Rag2</i>-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts.Mol Cancer Ther2018
29725697The impact of phosphatases on proliferative and survival signaling in cancer.Cell Mol Life Sci2018
29358171Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.Cancer Res2018
28504649Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.J Clin Invest2017
28961369Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.Proteomics2017
28504649Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.J Clin Invest2017
28961369Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.Proteomics2017
26507691All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.FEBS J2016
26507691All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase.FEBS J2016
26372073Reengineered tricyclic anti-cancer agents.Bioorg Med Chem2015
26372073Reengineered tricyclic anti-cancer agents.Bioorg Med Chem2015
28290285Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534].Bioorg Med Chem2015
28290285Corrigendum to "Reengineered tricyclic anti-cancer agents" [Bioorg. Med. Chem. 23 (2015) 6528-6534].Bioorg Med Chem2015
25453078Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.Proc Natl Acad Sci U S A2014
25453081Bisphosphonates inactivate human EGFRs to exert antitumor actions.Proc Natl Acad Sci U S A2014
25453078Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer.Proc Natl Acad Sci U S A2014
25453081Bisphosphonates inactivate human EGFRs to exert antitumor actions.Proc Natl Acad Sci U S A2014
22890320Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors.Oncogene2013
22890320Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors.Oncogene2013
22653055Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.J Clin Invest2012
22653055Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.J Clin Invest2012
21105123Lung adenocarcinoma: lessons in translation from bench to bedside.Mt Sinai J Med2010
21105123Lung adenocarcinoma: lessons in translation from bench to bedside.Mt Sinai J Med2010
  • 1 - 50 of 58

Recommended Authors

Anjali V Sheahan
Dana-Farber Cancer Institute
Career Start Year 2012
Number of shared co-authors 0
Victor Olivas
University of California san francisco
Career Start Year 2012
Number of shared co-authors 1
Luping Lin
Incyte Research Institute, Incyte Corporation
Career Start Year 2010
Number of shared co-authors 1
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Career Start Year 2010
Number of shared co-authors 0
Vibha Raghavan
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2009
Number of shared co-authors 0
Guo Chen
China Pharmaceutical University
Career Start Year 2009
Number of shared co-authors 0
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 4
Jaclyn LoPiccolo
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 0
John T Poirier
Laura and Isaac Perlmutter Cancer Center
Career Start Year 2007
Number of shared co-authors 2
Martin L Sos
University of Cologne, Faculty of Medicine and University Hospital Cologne
Career Start Year 2005
Number of shared co-authors 6
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 1
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 2
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Kristopher K Frese
Cancer Research UK Manchester Institute, University of Manchester
Career Start Year 2003
Number of shared co-authors 1
Ming Li
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 0
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 2
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 1
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 0
Michael Peyton
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
Career Start Year 1994
Number of shared co-authors 0
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 4
Nabeel Bardeesy
Massachusetts General Hospital
Career Start Year 1992
Number of shared co-authors 9
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 4
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 3
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 4
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 5
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 2
Ming-Sound Tsao
University Health Network, University of Toronto
Career Start Year 1972
Number of shared co-authors 2

Collaborators

Goutham Narla
The University of Michigan Medical School ann arbor
Co-authored papers 29
Analisa DiFeo
Co-authored papers 12
Sudeh Izadmehr
Co-authored papers 11
Caitlin M O'Connor
Co-authored papers 8
Michael Ohlmeyer
Atux Iskay LLC
Co-authored papers 8
Matthew D Galsky
Co-authored papers 8
Sahar Mazhar
Co-authored papers 6
Kimberly McClinch
Co-authored papers 5
David B Kastrinsky
Co-authored papers 5
Caroline C Farrington
Co-authored papers 5
Shozeb Haider
Co-authored papers 5
Neil S Dhawan
Co-authored papers 5
Danica D Wiredja
Co-authored papers 4
Nilesh Zaware
Co-authored papers 4
Agnes Stachnik
Co-authored papers 4
Daniela Schlatzer
Co-authored papers 4
Daniel Leonard
Co-authored papers 4
Rita A Avelar
Co-authored papers 3
David L Brautigan
Co-authored papers 3
Rosalie C Sears
Oregon Health and Science University
Co-authored papers 3
Abbey L Perl
Co-authored papers 3
Wenqing Xu
Co-authored papers 3
Zhizhi Wang
Co-authored papers 3
Eric Yuan
Co-authored papers 3
Rita Tohme
Co-authored papers 3
Daniel C McQuaid
Co-authored papers 2
Heather M Giannini
Co-authored papers 2
Shen Yao
Co-authored papers 2
Avi Ma'ayan
Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Divya Hoon
Co-authored papers 2
Release 1.2